Loperamida para el Síndrome de Intestino Irritable con Diarrea

Dosificación y Administración

• La loperamida tarda entre 1 y 2 horas en alcanzar su efecto terapéutico, por lo que las dosis adicionales deben espaciarse adecuadamente para evitar estreñimiento de rebote 1
• Para el SII-D, la titulación cuidadosa de la dosis puede ayudar a evitar efectos secundarios como dolor abdominal, distensión, náuseas y estreñimiento 2

Eficacia en SII-D

• La loperamida es un tratamiento de primera línea eficaz para la diarrea en el SII-D, aunque los efectos secundarios como dolor abdominal, distensión, náuseas y estreñimiento pueden limitar su tolerabilidad 2
• Los estudios muestran que la loperamida mejora significativamente la consistencia de las heces y la frecuencia de las deposiciones en pacientes con SII-D 3
• La loperamida ha demostrado proporcionar alivio adecuado del dolor abdominal (RR, 0,41; IC del 95%, 0,20-0,84) y mejoría en la consistencia de las heces (RR, 0,06; IC del 95%, 0,01-0,43) en comparación con placebo 4

Consideraciones de Uso

• La loperamida puede ser utilizada de forma regular o profiláctica (por ejemplo, antes de salir) en dosis de 4-12 mg diarios 5

Mecanismo de Acción

• La loperamida es un agonista opioide periférico sintético que inhibe la peristalsis, tiene actividad antisecretora y prolonga el tiempo de tránsito intestinal con penetración limitada de la barrera hematoencefálica 3, 4
• Está aprobada por la FDA para el tratamiento de pacientes con diarrea aguda, crónica y del viajero 4

Advertencias y Precauciones

• Si la diarrea empeora o está acompañada de síntomas moderados-graves o invasivos (por ejemplo, fiebre, dolor abdominal moderado a grave o diarrea con sangre), se deben usar antibióticos 1

Algoritmo de Tratamiento para SII-D

• Evaluar la respuesta después de 3-5 semanas de tratamiento 4
• Si hay mejoría en la consistencia de las heces y el dolor abdominal, continuar con la dosis efectiva 4
• Si no hay mejoría o los efectos secundarios son intolerables, considerar otras opciones terapéuticas como antidepresivos tricíclicos, antagonistas de los receptores 5-HT3 o eluxadolina 3, 4

Loperamide for Irritable Bowel Syndrome with Diarrhea

Introduction to Loperamide Treatment

• The American Gastroenterological Association recommends loperamide as a first-line treatment for IBS-D at doses of 4-12 mg daily, primarily improving stool consistency and frequency rather than global IBS symptoms or urgency 6

Clinical Efficacy Profile

• Loperamide significantly improves stool consistency (RR 0.06; 95% CI 0.01-0.43) and reduces stool frequency in patients with IBS-D, with a relative risk reduction of 94% 6, 7, 8
• Loperamide provides adequate relief of abdominal pain (RR 0.41; 95% CI 0.20-0.84) in some patients with IBS-D, with a relative risk reduction of 59% 6, 7, 8
• Loperamide does not improve urgency symptoms or global IBS symptoms reliably in patients with IBS-D 6, 7, 8

Treatment Algorithm for IBS-D

• The British Society of Gastroenterology recommends considering tricyclic antidepressants (amitriptyline 10 mg once daily, titrated to 30-50 mg) as second-line gut-brain neuromodulators for global symptoms and pain in patients with IBS-D who do not respond to loperamide 6, 9
• The British Society of Gastroenterology suggests 5-HT3 receptor antagonists (ondansetron 4-8 mg) as highly efficacious second-line options in secondary care for patients with IBS-D, though constipation is common 9

Evidence Quality Considerations

• The recommendation for loperamide carries a conditional strength due to very low certainty evidence, with only two small studies from 1987 supporting its use, conducted before modern trial standards 6, 7, 8

Treatment of Diarrhea-Dominant IBS

Introduction to Second-Line Treatments

• The American Gastroenterological Association recommends tricyclic antidepressants, such as amitriptyline 10 mg at bedtime, titrated to 30-50 mg, as the next treatment step for patients with diarrhea-dominant IBS who have not responded adequately to loperamide, as they function as gut-brain neuromodulators that improve global IBS symptoms, abdominal pain, and normalize rapid small bowel transit 10, 11

Second-Line Treatment Options

• Tricyclic antidepressants, such as amitriptyline, normalize rapid small bowel transit in IBS-D and provide significant benefit for abdominal pain in large randomized controlled trials, with constipation being the most significant side effect, which can actually be beneficial in IBS-D 12, 13
• The use of 5-HT3 receptor antagonists, such as ondansetron 4 mg once daily, titrated to maximum 8 mg three times daily, is likely the most efficacious drug class for IBS-D, with the most accessible option being ondansetron 11
• Alosetron 0.5 mg twice daily, can increase to 1 mg twice daily after 4 weeks if tolerated, is FDA-approved but only for women with severe IBS-D, with a major limitation being constipation as the most common side effect, and carrying serious risks such as ischemic colitis and serious complications of constipation 10, 11

Antibiotic Therapy

• Rifaximin 550 mg three times daily for 14 days, has a moderate efficacy with a 9% absolute benefit over placebo for global symptom relief, and can be repeated for up to two additional 14-day courses if symptoms relapse, with the most favorable safety profile among FDA-approved agents 10, 11

Special Considerations

• In approximately 10% of IBS-D patients, bile salt malabsorption may be the underlying cause, and cholestyramine is effective if 75SeHCAT retention is <5%, however, tolerability is poor, and many patients prefer loperamide which is equally effective 12, 13